Asset Details
Do you wish to reserve the book?
Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension
Do you wish to request the book?
Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Survival of Japanese Patients With Idiopathic/Heritable Pulmonary Arterial Hypertension
2017
Overview
Idiopathic/heritable pulmonary arterial hypertension has a poor prognosis despite the available therapeutic options. Survival of Japanese patients with this disease entity has not been reported in the multicenter setting. A retrospective study of 141 patients with idiopathic/heritable pulmonary arterial hypertension treated at 3 pulmonary hypertension centers in Japan from 1992 to 2012 investigated survival and determinants of survival. Mean survival time from treatment initiation was 14.7 ± 0.8 years (95% confidence interval, 13.1 to 16.3 years) and the 1-, 3-, 5-, and 10-year survival rates were 97.9%, 92.1%, 85.8%, and 69.5%, respectively. Patients showed significant improvement in exercise capacity and hemodynamics after treatment. Patients with 6-minute walk distance >372 m, mean pulmonary arterial pressure ≤46 mm Hg, and cardiac index >2.5 L/min/m2 at follow-up had a significantly better prognosis. Most patients (99.2%) were receiving pulmonary hypertension-targeted drugs at follow-up. Use of endothelin receptor antagonists and intravenous epoprostenol were related to survival in the univariate analysis. Among the patients who were on intravenous epoprostenol therapy, those with endothelin receptor antagonists had a significantly better prognosis, whereas patients on warfarin had a significantly worse prognosis. In conclusion, survival of Japanese patients with idiopathic/heritable pulmonary arterial hypertension in this study was good, showing improvement in hemodynamic parameters supported by pulmonary hypertension-targeted drugs.
Publisher
Elsevier Inc,Elsevier Limited
Subject
/ Adult
/ Antihypertensive Agents - therapeutic use
/ Endothelin Receptor Antagonists - therapeutic use
/ Epoprostenol - therapeutic use
/ Exercise Tolerance - physiology
/ Familial Primary Pulmonary Hypertension - blood
/ Familial Primary Pulmonary Hypertension - mortality
/ Familial Primary Pulmonary Hypertension - physiopathology
/ Familial Primary Pulmonary Hypertension - therapy
/ Female
/ Heart
/ Humans
/ Japan
/ Male
/ Natriuretic Peptide, Brain - blood
/ Patients
/ Survival
/ Warfarin
